YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Pile of money with hands by Sergey Nazarov via iStock Achieve Life Sciences (ACHV) is a $685 million biotech focused on cytisinicline-based nicotine addiction treatments, showing strong recent technical momentum. ACHV has surged 173% over…
* Achieve Life Sciences press release [https://seekingalpha.com/pr/20614674-achieve-life-sciences-reports-second-quarter-2026-financial-results-and-provides-business] (ACHV [https://seekingalpha.com/symbol/ACHV]): Q2 GAAP EPS of -$0.80 mis…
Key Points Interested in Achieve Life Sciences, Inc.? Here are five stocks we like better. Achieve Life Sciences held its 2026 annual meeting and presented a slate of nine directors for election, including CEO Andrew Goldberg and several c…
SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commerciali…
(RTTNews) - This week, the biotech sector delivered a mix of FDA and EU approvals, strategic reorganizations, layoff, acquisitions, and late-stage clinical readouts across oncology, metabolic disease, neurology and immunology. Regulatory m…
CRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficiencies Identified SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Comp…
Achieve Life Sciences Appointments Add Deep Biopharmaceutical Commercial Strategy, Clinical and Finance Expertise as Company Advances Toward Potential Cytisinicline Approval and Launch SEATTLE and VANCOUVER, British Columbia, June 02, 2026…
(RTTNews) - Achieve Life Sciences, Inc. (ACHV), a late-stage specialty pharmaceutical company, announced the presentation of long-term safety data from the ORCA-OL study evaluating its lead investigational candidate, Cytisinicline, for tre…
ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous exposure Nausea — a com…
Major earnings expected before the bell on Tuesday include: * JD.com (JD [https://seekingalpha.com/symbol/JD]) * Sea Limited (SE [https://seekingalpha.com/symbol/SE]) * D-Wave Quantum (QBTS [https://seekingalpha.com/symbol/QBTS]) * Lithium…
Achieve Life Sciences, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Transformation and Operational Context Transitioned from a clinical development firm to a commercially focused enterprise following the June 2025 NDA submission for…
By John Vandermosten, CFA NASDAQ: ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ: ACHV) reported 2025 results following the submission of a new drug application (NDA) to the FDA and the assignment of cytisinicl…
Major earnings expected before the bell on Tuesday include: * Xiaomi Corporation (XIACF [https://seekingalpha.com/symbol/XIACF]) * Vertical Aerospace Ltd. (EVTL [https://seekingalpha.com/symbol/EVTL]) * Concentrix Corporation (CNXC [https:…
We came across a bullish thesis on Achieve Life Sciences, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ thesis on ACHV. Achieve Life Sciences, Inc.'s share was trading at $4.18 as of January 30th. Achieve Li…
SEATTLE and VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline a…
Achieve Life Sciences Inc. (NASDAQ:ACHV) is one of the Canadian penny stocks to buy right now. Lake Street’s Thomas Flaten maintained a Buy rating on Achieve Life Sciences Inc. (NASDAQ:ACHV) at $11.00 on November 7.FDA Accepts Achieve Life…
Earnings Call Insights: Achieve Life Sciences (ACHV) Q3 2025 MANAGEMENT VIEW * CEO Richard A. Stewart described the quarter as "another truly significant quarter for Achieve in our mission to get a new treatment for nicotine dependence int…
One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and VANCOUVER, British Columbia,…
120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully Concluded DSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE…
SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline a…
SEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline f…
This article first appeared on GuruFocus. The FDA issued the first-ever Commissioner's National Priority Vouchers (CNPVs), a move meant to speed reviews for treatments that address urgent public-health needs, according to an Oct. 17 press…
This article first appeared on GuruFocus. Introduction Valero Energy manufactures, markets, and sells fuel. While the company is in a strong market position, the valuation looks stretched considering the negative outlook for non-renewable…
Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway One of Only Nine Therapies Chosen for the FDA’s Inaugural National Priority Voucher Program SEATTLE and VANCOUV…
[US Food and Drug Administration (FDA)] Achieve Life Sciences (NASDAQ:ACHV [https://seekingalpha.com/symbol/ACHV]), Disc Medicine (NASDAQ:IRON [https://seekingalpha.com/symbol/IRON]), and Revolution Medicines (NASDAQ:RVMD [https://seekinga…
SEATTLE and VANCOUVER, British Columbia, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline f…
SEATTLE and VANCOUVER, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline…
SEATTLE and VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline…
* Achieve Life Sciences (NASDAQ:ACHV [https://seekingalpha.com/symbol/ACHV]) said that [https://seekingalpha.com/pr/20230175-achieve-life-sciences-names-dr-mark-rubinstein-interim-chief-medical-officer] Mark Rubinstein, M.D., will assume t…
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline…
[Cigarette with prohibition sign on wooden table, top view. Quitting smoking concept] Liudmila Chernetska/iStock via Getty Images * Achieve Life Sciences (NASDAQ:ACHV [https://seekingalpha.com/symbol/ACHV]) said that the U.S. FDA will revi…
SEATTLE and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline…
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT OSRH [https://w…
Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a potential first new smoking cessation therapy in nearly two decades, positioning the company for a high-stakes comm…
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported its second quarter 2025 results and highlighted several milestones achieved since the last quarterly update. This i…
Achieve Life Sciences Inc (NASDAQ:ACHV [https://www.chartmill.com/stock/quote/ACHV/profile]) reported its second-quarter 2025 financial results, posting revenue of $0.0 and an earnings per share (EPS) loss of $0.37. These figures were larg…